Into its seventh year, WuXi Global Forum 2019 continues its tradition of bringing together thousands of leaders onsite and via live broadcasting to promote new thinking on a global stage.
Innovation is at the core of the healthcare system. In this panel, some of our industry’s top leaders bring together diverse and fresh perspectives on new ways to enhance connectivity, productivity, and efficiency in delivering better medicines for patients.
Moderator: Edward Hu, Co-CEO, WuXi AppTec
Mathai Mammen, Global Head, Research & Development
The Janssen Pharmaceutical Companies of Johnson & Johnson
Tom Lynch, EVP and CSO, BMS
Laurie Glimcher, President and CEO, Dana-Faber Cancer Institute
Moncef Slaoui, Partner, Medicxi Life Sciences VC
From tough targets to disruptive technologies to new modalities, this panel of startup CEOs and investors explain their bold moves, and what will shape 2019 and beyond.
Moderator: Michael Gilman, Chairman and CEO, Arrakis Therapeutics
Bob Hariri, Founder, Chairman and CEO, Celularity
Sander Slootweg, Managing Partner, Forbion
John Evans, CEO, Beam Therapeutics; Venture Partner, ARCH Venture Partners
Andy Schwab, Managing Partner, 5AM Ventures
Healthcare is ripe for transformation. What is the magic touch that effects change? We ask two visionaries on the 2018 Forbes Midas List of the world’s top venture capital investors to share their thoughts.
Moderator: Steve Yang, EVP and CBO, WuXi AppTec
Neil Shen, Global Steward, Sequoia Capital; Founding and Managing Partner, Sequoia China
Robert Nelsen, Managing Director and Co-Founder, ARCH Venture Partners
How would the future of R&D and healthcare look like in a world involving real-world evidence and decision making informed by genomics, big data, and artificial intelligence?
Moderator: Robert Urban, Retired Global Head of Johnson & Johnson Innovation
Blake Byers, General Partner, Google Ventures
Daphne Koller, CEO and Founder, insitro
Rob Brainin, CEO, WuXi NextCODE
Ken Mulvany, Founder and Chairman, BenevolentAI
Deb Kilpatrick, CEO, Evidation Health
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances, and Head of PR and Corporate Communications.
Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS), a member of BayHelix, and a member of the UCSD Alumni Board. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar
Dr. Ge Li is one of the most influential leaders in the global biopharma R&D industry. He pioneered an integrated R&D service model and the open-access R&D enabling platform model with the conviction that more efficient and cost-effective R&D should be at the core of better medicines for patients, and that “every drug can be made and every disease can be treated.” As the company’s Chairman, Dr. Li has led WuXi’s rapid growth from four employees and a single Chemistry lab of 7,000 square feet in December 2000 to a transformative global R&D powerhouse with more than 22,000 employees worldwide, enabling over 3,000 collaborative partners worldwide. Dr. Li earned his Bachelor’s degree in Chemistry from Peking University and his doctoral degree in Organic Chemistry from Columbia University.
Mr. Edward Hu is currently Co-CEO at WuXi AppTec. With experience in operational excellence, financial management and global business expansion, Mr. Hu has demonstrated his extraordinary leadership to help the business expand further.
Since joined WuXi in 2007, Mr. Hu has served as the company’s Chief Operating Officer, and later Chief Financial Officer and Chief Investment Officer. Over the past decade, he has scored significant achievements in WuXi’s rapid development. Mr. Hu was elected to the Board of Directors in March 2016.
Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox. His earlier career spanned managerial and financial positions at Biogen and Merck respectively. Mr. Hu has an MBA and Master’s degree in Chemistry from Carnegie Mellon University.
As Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Mathai’s mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity. The team works across a wide range of therapeutic areas and biological pathways. Janssen’s approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality. The team is invested deeply in data sciences in every aspect of R&D. Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world.
Prior to Janssen, Mathai was SVP at Merck Research Laboratories, and with his team he initiated numerous new programs and progressed eight into early clinical development. At Theravance, a company he co-founded in 1997 based on his work at Harvard University, his talented team nominated 31 development candidates in 17 years, created four approved products, and filed for approval of a fifth.
Mathai has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry.
Dr. Thomas Lynch joined Bristol-Myers Squibb in March 2017 as Chief Scientific Officer to lead the Research & Development organization bringing broad leadership experience, significant experience in drug development and a deep understanding of the patient perspective as a treating oncologist. He previously served as a Director on Bristol-Myer Squibb’s Board from 2013-2017.
Tom has more than 30 years of medical, management and leadership experience, including more than 23 years at Massachusetts General Hospital (MGH). He served as Chairman and Chief Executive Officer of Massachusetts General Physicians Organization and as a member of the MGH Board from 2015 to 2017.
Before his roles as Chairman and CEO at MGH, Tom served as the Director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine from 2009 to 2015. He also served as the Physician in Chief of Smilow Cancer Hospital, Yale New Haven from 2009 to 2015. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. While at MGH in 2004, Tom was part of the team credited with the significant discovery that certain genetic mutations in lung cancer patients caused therapies to work for some individuals and not for others.
Tom is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.
Laurie H. Glimcher, MD is the President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher, a member of the National Academy of Sciences, is a widely renowned trailblazer in cancer and immunology research. She served on the Board of Directors of Bristol Myers Squibb Pharmaceuticals and is currently a Director of GlaxoSmithKline Pharmaceuticals and the Waters Corporation.
Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first woman to be appointed as dean of Weill Cornell Medicine in New York and is the first female President and CEO of Dana-Farber Cancer Institute.
Moncef is a Partner at Medicxi and has been with the firm since September 2017. He currently serves on the board of Divide & Conquer and has an active role in several other Medicxi portfolio companies to support their development.
Prior to Medicxi, Moncef was GlaxoSmithKline’s Head of Pharmaceutical R&D and Chairman of its Vaccines division. From this leadership role, Moncef spearheaded a profound overhaul of GSK’s pharmaceutical R&D, resulting in a substantial improvement in productivity, a late-stage pipeline comprising more than 30 phase 3 programmes and a totally redesigned discovery organisation comprising 38 highly focused and accountable Discovery Performance Units. During his career at GSK, he also headed the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent pneumococcal disease and Cervarix to prevent cervical cancer.
Outside of his role at Medicxi, Moncef is chairman of the board at Galvani Bioelectronics, chairman of the board at SutroVax and sits on the boards of Artisan Biosciences, Human Vaccines Project and Moderna Therapeutics.
Moncef received a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of Immunology at the University of Mons, Belgium and has authored more than 100 scientific papers and presentations. A citizen of Morocco, Belgium and the USA, he is fluent in English, French and Arabic.
Michael Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. Mike currently serves as Chairman and Chief Executive Officer of Arrakis Therapeutics and Chief Executive Officer and Director of Obsidian Therapeutics. Mike also serves on the Board of Directors of Scholar Rock and X4 Pharmaceuticals and on the Scientific Advisory Board of Scholar Rock and FutuRx, a biotech accelerator in Israel. He is also an Advisor at Atlas Venture. Previously, Mike was Founder and Chief Executive Officer of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Prior to Padlock, Mike served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, Mike was Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Mike was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Mike was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Mike was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.
Dr. Hariri has worked for the past 20 years to transform the field of biomedicine where his discoveries and contributions to the study of stem cells and tissue engineering have sparked the development of nearly all existing stem cell therapies. In addition to Celularity, he is the Founder, and former Chairman and CEO of Celgene Cellular Therapeutics, a division of Celgene Corporation. He is also the Co-Founder and Vice Chairman of Human Longevity Inc.
Sander is a Founder and Managing Partner at Forbion, a leading European Life Sciences VC firm. In addition to his leading role on its investment team, he is responsible for Fundraising, Investor- and Public Relations at Forbion. On the portfolio management side, he currently serves on the boards of portfolio companies Replimune (REPL), NorthSea (Chair), Xention and Oxyrane.
Sander was a.o. responsible for the sale of Dezima to Amgen in 2015 for up to USD 1.55 billion and Biovex to Amgen in March of 2011 for up to USD 1 billion. In recent years Sander has also served on the boards of Fovea (sold to Sanofi in 2009), uniQure (IPO on Nasdaq in 2014), Argenta (sold to Galapagos in 2010), Pieris (IPO on Nasdaq in 2015), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007) and Impella (sold to Abiomed in 2005).
Before founding Forbion, he was a co-founder of ABN AMRO Capital Life Sciences in 2000. His other activities at ABN AMRO Bank included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami).
Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands.
John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners.
Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals (AGIO), most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA (AG-221) and AG-120. He helped initiate and lead Agios’s landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple innovative research collaborations in cancer metabolism. He also initiated and co-led Agios’s strategic expansion into rare genetic diseases of metabolism. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals as program executive for the company’s Hsp90 inhibitors. He has also worked at McKinsey & Company (Pharmaceuticals practice), MedImmune, and Bayer Pharmaceuticals.
Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.
Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Biodesy, Bird Rock Bio, Cleave, DVS (acquired by Fluidigm), Escient, Flexion (NASDAQ: FLXN), Ikaria (acquired by Mallinckrodt and spun-out Bellerophon (NASDAQ: BLPH), Ilypsa (acquired by Amgen), Panomics (acquired by Affymetrix), Pear Therapeutics, Precision NanoSystems, Purigen, Synosia (acquired by Biotie) and Viveve (NASDAQ: VIVE). Mr. Schwab also serves on the Boards of Trustees of the California Academy of Sciences, Davidson College and the National Venture Capital Association (NVCA). Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of its 1992 Final Four soccer team.
Dr. Steve Yang is Executive Vice President and Chief Business Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. His responsibilities include management of multiple business units and commercial operation. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device R&D capability and technology open access platform company with operations in China, US, and Europe.
Dr. Yang is a pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer’s global R&D strategic management group based in the United States.
Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude from Michigan Technological University. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as the chairman of the board for two terms.
Neil Shen serves on a number of philanthropic and public sectors and industry associations, including as Trustee of Brookings Institution, Member of the Hong Kong Chief Executive’s Council of Advisors on Innovation and Strategic Development, Member of Hong Kong Financial Services Development Council, Governor of Our Hong Kong Foundation, Director of Yabuli China Entrepreneur Forum (CEF), Trustee of Asia Society, Trustee of Shanghai Jiao Tong University and Chairman of Yale Center Beijing Executive Council.
Neil Shen has received numerous honors and awards in China and across the globe. Neil Shen’s ascent to the top of the 2018 Midas List marks a milestone – the first time that a Chinese national has hit the top of the list. He was the highest ranking Chinese investor on Forbes Midas List for the year from 2012 to 2018, and also listed in the “100 Greatest Living Business Minds” by Forbes. In addition, he was amongst “50 Most Influential Business Leaders in China” and “30 Most Influential Investors in China” by Fortune for the year from 2015 to 2017, and “Top 20 Venture Capitalists Worldwide” by New York Times and CB Insights in 2017.
He received his Master’s degree from Yale University and Bachelor’s degree from Shanghai Jiao Tong University.
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation.
Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Until retiring in 2018, Robert G. Urban served as the Global Head of Johnson & Johnson Innovation, LLC. – A distinct business unit of J&J that serves as the Company’s enterprise-level externally facing R&D investment platform. Under his leadership, the J&J Innovation brand and global platform was launched and became the #1 recognized cross-sector (pharm, med device and consumer) innovation leader with a portfolio encompassing over 400 individual investments, including a globally distributed suite of incubators (JLABS) hosting over 300 start-ups. Prior to joining J&J, Robert was the founding Executive Director of Massachusetts Institute of Technology’s (MIT) Koch Institute for Integrative Cancer Research. He was previously the CEO of Acretia Inc., a privately held intellectual property arbitrage organization and has co-founded and/or served on the Board of several companies and organizations.
Blake is an engineer, scientist, and entrepreneur who has been working at GV since 2010. As an investor, Blake partners with founders on life-science and digital companies — from drug development and healthcare delivery to financial services and information security.
Blake’s life science investments include Denali (Nasdaq: DNLI), Armo (Acquired by Lilly), Forty Seven (Nasdaq: FTSV), Magenta (Nasdaq: MGTA) and Arcus (Nasdaq: RCUS). Blake’s digital investments include being the first investor in Robinhood and Gusto.
Prior to GV, Blake helped start two companies, led research projects on biomedical engineering and stem cell biology at Stanford, and was an angel investor.
Blake received a Ph.D. and master’s in bioengineering from Stanford University and holds Bachelor of Science degrees in biomedical engineering and economics from Duke University.
Daphne Koller is the CEO and Founder of insitro, a startup company that aims to rethink drug development using machine learning. Daphne was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years. She was the co-founder, co-CEO and President of Coursera for 5 years, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 200 refereed publications appearing in venues such as Science, Cell, and Nature Genetics. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004 and the ACM Prize in Computing in 2008. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.
Rob Brainin is a global life sciences and healthcare executive with over twenty years of industry experience, with a strong focus on genomics and innovation. He currently serves as the CEO of WuXi NextCODE. In prior work experiences, Rob served as a General Manager across a variety of life sciences areas during his roles with Illumina, Life Technologies, Invitrogen, and Thermo Fisher.
His ambition is to optimize genomic technologies and information into real-life solutions, which has current and developing potential applications within healthcare. As health care systems, clinicians, researchers, therapeutic developers, foundations, patient families, and individuals seek to improve areas of genomic understanding, Rob seeks to help them take complex genomic information and make it actionable in a meaningful way.
He also serves on the Board of Directors of the Children’s Tumor Foundation, a foundation focused on driving research and seeking cures for Neurofibromatosis, a rare genetic disease that impacts 1 in 3,000 people, including his own daughter. Rob holds an undergraduate degree in Economics (with honors) from Emory University and a J.D. (cum laude) from Harvard Law School.
Mr. Ken Mulvany is a serial entrepreneur and investor with more than 20 years of business leadership experience. He is the Founder and Chairman of BenevolentAI, a $2bn machine intelligence company with end-to-end drug development capabilities. Mr. Mulvany was previously Founder and CEO of Proximagen, a leading biotech company developing medicines for central nervous system disorders, which he sold in 2012. Mulvany sits on several advisory boards including the advisory panel to the UK Government on Artificial Intelligence and the Advisory Board for Oxford Sciences Innovations. He is a member of the All-Party Parliamentary Group on Artificial Intelligence, and formerly, the Chairman of the Trustees of the Cure Parkinson’s Trust. Mr. Mulvany is a world champion sailor and competed in the 1992 America’s Cup.
Deborah Kilpatrick, PhD is the CEO of digital health company Evidation Health in San Mateo, CA. Evidation is a new kind of health and measurement company that provides the world’s most innovative healthcare companies technology and expertise to understand how everyday behavior and health interact. Previously, Deborah was the Chief Commercial Officer of genomic diagnostics company CardioDx, whose Corus CAD product was named in the Wall Street Journal Technology Innovation Awards and TIME Magazine’s Top 10 Medical Breakthroughs. Earlier in her career, she held multiple leadership roles in R&D and New Ventures at Guidant Corporation prior to its acquisition by Boston Scientific (NYSE: BSX). She currently sits on the Georgia Tech College of Engineering Advisory Board, is a Director for Sleep Number (NASDAQ: SNBR), and is a Fellow of the American Institute of Medical and Biological Engineering. A co-founder of the MedtechVision Conference now held annually in Silicon Valley, Deborah has also has been named to FierceBiotech’s Top Women in Biotech and FierceMedicalDevice’s Top Women in Medtech. She holds B.S., M.S. and Ph.D. degrees in engineering from Georgia Tech.
Joseph Panetta is President and CEO and a member of the Board of Directors of Biocom, California’s largest and most-experienced leader and advocate for the life science industry. Biocom works on behalf of over 1,100 members to drive public policy, build an enviable network of industry leaders, create access to capital development, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs. Mr. Panetta works with an experienced professional staff of 50, with offices located in San Diego, Los Angeles, San Francisco Bay Area, Tokyo, and Washington, D.C.
Mr. Panetta is co-founder of the Biocom Political Action Committee, the Biocom Institute for education and workforce development, and chairman of the California Biotechnology Foundation. In 2014, Mr. Panetta was appointed by California Governor Jerry Brown to the Independent Citizens Oversight Committee, which serves as the governing and oversight board for the California Institute for Regenerative Medicine (CIRM) and is responsible for providing grant funding under the $3 billion California Stem Cell Initiative.
Mr. Panetta holds a Bachelor of Science degree in biology from LeMoyne College, and a Master of Public Health degree in industrial and environmental health from the University of Pittsburgh. Mr. Panetta brings a depth of experience to his role, having worked in the life science industry at companies including Dow AgroSciences, Mycogen, Shearing AG, and Pennwalt Corp. He also served as a senior policy analyst at the U.S. Environmental Protection Agency in Washington, D.C. Mr. Panetta joined Biocom in 1999.